Taysha Gene Therapies (TSHA) stock
TSHA's Quality Score fell 1 point on Fri, Oct 2, to -6.
Follow TSHA's trial news. Pro members can get an alert when Taysha Gene Therapies files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for TSHA, and how long its cash lasts
From Taysha Gene Therapies’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into 2H 2028 (8-K, Aug 11).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Nov 4, 2025)
- At-the-market share sales program (S-3ASR, filed Nov 4, 2025)
Insiders
An officer, Sukumar Nagendran, sold 200,000 shares on Jul 10, under a planned sale. 6 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 25 daysINOInovio Pharmaceuticals
INOINO-3107
- In 36 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 48 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 27% in 3 months, 18% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Growth sales down 32% on the year, operating margin down 1631.5 points
5 more things pulling TSHA's score down, for Pro members
What's next
Wed Oct 14: 55th Child Neurology Society (CNS)…Industry event · date confirmed.
Expected to report Wed Nov 4, after the close
After its last 4 reports it closed -1.3% on average, higher 2 of 4 times.
What would turn TSHA's score around: 9 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
TSHA has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1432.9
- MACD (12, 26, 9)Below signal
- 50-day average$5.62
- 200-day average$5.46
- ADX 1419.1
- Support$4.43
- Resistance$4.77
- Bollinger Bands (20, 2)Inside
- Volume0.8x
How TSHA ranks in Biotech
TSHA is #267 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
TNGXOpen for its score
TRDAOpen for its score
TVTXOpen for its score
TWSTOpen for its score
TSHA1/14-6
When does TSHA report earnings, and what happens after?
Expected to report Wed Nov 4, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 11, 2026After close | After close | -8.2% | -4.1% | -7.3% |
| May 6, 2026Before open | Before open | -4.8% | +0.6% | -1.3% |
| Mar 19, 2026Before open | Before open | +2.3% | +2.5% | +2.9% |
| Nov 4, 2025Before open | Before open | -3.8% | -4.3% | -12.8% |
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of TSHA's score, with the points and the reason
- All 14 checks on TSHA and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on TSHA
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.